Kaken Pharmaceutical

This completed Phase 1 study tested a single 50 mg dose of the drug KP-001 in 24 adults, some with healthy livers and others with different levels of liver impairment. The goal was to see how liver function affects the drug's levels and safety in the body. Results could help guid…

This study checks whether a new drug called KP-001 affects the heart's electrical activity (QT interval) in 40 healthy adults. Participants receive single doses of KP-001, a placebo, or moxifloxacin (a control drug known to affect the QT interval) in random order. The goal is to …

This completed Phase 1 study looked at how a new drug called KP-001 interacts with other medications in 38 healthy adults. The study measured how KP-001 affects the body's processing of rosuvastatin (a cholesterol drug) and caffeine, and how fluvoxamine (an antidepressant) affect…